<DOC>
	<DOCNO>NCT00227695</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody , rituximab , block cancer growth different way . Some block ability cancer cell grow spread . Others find cancer cell help kill carry cancer-killing substance . It yet know whether give rituximab short period time effective give long period time treat follicular non-Hodgkin 's lymphoma . PURPOSE : This randomized phase III trial study rituximab see well work give short period time compare give long period time treat patient follicular non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Rituximab Treating Patients With Follicular Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare efficacy induction therapy rituximab follow short- v long-term maintenance therapy rituximab , term event-free survival , patient follicular non-Hodgkin 's lymphoma . Secondary - Compare safety regimens patient . - Compare pharmaeconomical aspect regimens patient . - Compare evolution immunologic competence patient treat regimen . OUTLINE : This randomize , multicenter study . - Induction therapy : Patients receive rituximab IV weekly week 1-4 undergo restaging week 11-13 . Patients stable disease progressive disease take study . Patients achieve partial complete response stratify accord prior treatment status ( untreated* v treat without anti-CD20 therapy ) , presence bulky disease** study entry ( yes v ) , participate center . Patients randomize 1 2 maintenance treatment arm . NOTE : *Patients treat radiotherapy consider therapy-naïve . NOTE : **Defined mass lymph node conglomerate ≥ 5 cm diameter . - Maintenance therapy : Patients start maintenance therapy within 7 day randomization . - Arm I : Patients receive rituximab IV every 2 month 4 treatment . - Arm II : Patients receive rituximab IV every 2 month 5 year absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 3 month disease progression relapse annually 10 year randomization . PROJECTED ACCRUAL : A total 270 patient accrue study within 3 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm follicular lymphoma Grade 1 , 2 , 3a , 3b disease WHO stag system CD20positive immunohistochemistry Previously untreated disease OR meet 1 follow criterion response prior treatment : Chemotherapyresistant disease Relapsed progressive disease Stable disease At least 12 week since prior systemic treatment At least 1 bidimensionally measurable lesion ≥ 11 mm CT scan MRI No transformation highgrade lymphoma secondary lowgrade follicular lymphoma No prior current CNS disease ( i.e. , CNS lymphoma lymphomatous meningosis ) NOTE : A new classification scheme adult nonHodgkin 's lymphoma adopt PDQ . The terminology `` indolent '' `` aggressive '' lymphoma replace former terminology `` low '' , `` intermediate '' , `` high '' grade lymphoma . However , protocol us former terminology . PATIENT CHARACTERISTICS : Age 18 Performance status WHO 02 Life expectancy Not specify Hematopoietic Not specify Hepatic Not specify Renal Not specify Cardiovascular Ejection fraction ≥ 50 % echocardiography MUGA Immunologic No acute ongoing infection No HIV infection No active autoimmune disease Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 12 month completion study treatment No uncontrolled diabetes mellitus No medical condition would preclude study participation No malignancy except nonmelanoma skin cancer adequately treat carcinoma situ cervix No condition ( e.g. , geographic proximity ) would preclude study compliance followup PRIOR CONCURRENT THERAPY : Biologic therapy See Radiotherapy Prior rituximab allow Chemotherapy See Disease Characteristics Endocrine therapy More 4 week since prior regular administration corticosteroid Dose equivalent ≤ 20 mg/day prednisone allow condition lymphoma lymphomarelated symptom No concurrent corticosteroid prevention treatment side effect except acute lifethreatening side effect Radiotherapy Prior radiolabeled antiCD20 therapy ( administer alone combination cytostatic drug ) allow provided patient achieve partial complete response therapy At least 12 month since prior antiCD20 therapy Surgery Not specify Other More 30 day since prior systemic tumor therapy More 30 day since prior participation another clinical trial No concurrent anticancer therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>stage I grade 1 follicular lymphoma</keyword>
	<keyword>stage I grade 2 follicular lymphoma</keyword>
	<keyword>stage I grade 3 follicular lymphoma</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>contiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>contiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>contiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
</DOC>